Cargando…

Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest

OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a sele...

Descripción completa

Detalles Bibliográficos
Autor principal: Grigorescu, Alexandru C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936471/
https://www.ncbi.nlm.nih.gov/pubmed/27847881
http://dx.doi.org/10.4103/2224-4018.154291
_version_ 1782441568316162048
author Grigorescu, Alexandru C.
author_facet Grigorescu, Alexandru C.
author_sort Grigorescu, Alexandru C.
collection PubMed
description OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). MATERIALS AND METHODS: The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0–1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. RESULTS: 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. CONCLUSIONS: For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy.
format Online
Article
Text
id pubmed-4936471
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher De Gruyter Open
record_format MEDLINE/PubMed
spelling pubmed-49364712016-11-15 Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest Grigorescu, Alexandru C. J Transl Int Med Original Article OBJECTIVES: First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). MATERIALS AND METHODS: The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0–1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. RESULTS: 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. CONCLUSIONS: For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy. De Gruyter Open 2015 2015-03-30 /pmc/articles/PMC4936471/ /pubmed/27847881 http://dx.doi.org/10.4103/2224-4018.154291 Text en Copyright © International Society of Translational Sciences This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License (CC BY-NC-ND 3.0) (http://creativecommons.org/licenses/by-nc-nd/3.0/)
spellingShingle Original Article
Grigorescu, Alexandru C.
Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title_full Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title_fullStr Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title_full_unstemmed Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title_short Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
title_sort chemotherapy for elderly patients with advanced cancer: a pilot study in institute of oncology bucharest
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936471/
https://www.ncbi.nlm.nih.gov/pubmed/27847881
http://dx.doi.org/10.4103/2224-4018.154291
work_keys_str_mv AT grigorescualexandruc chemotherapyforelderlypatientswithadvancedcancerapilotstudyininstituteofoncologybucharest